Presentation on theme: "Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M."— Presentation transcript:
Bevacizumab (Avastin): 2 year results in choroidal neovascularization (CNV) secondary to pathologic myopia (PM). regory S. Brinton; Sayed S E H Saif; M. Yasser S. Saif; Ahmed T.S. Saif No Financial Interest
M. Yasser S. Saif,MD* Ahmed T.S. Saif, MD** Gregory S. Brinton, MD*** Sayed S E H Saif, MD**** *Assistant Prof of ophthalmology Beni sueif university ** lecturer of ophthalmology Fayoum university ***Prof of ophthalmology Utah university ****Prof of ophthalmology Cairo university
PURPOSE: To evaluate the safety and efficacy of intravitreal bevacizumab in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia (PM). DESIGN: Prospective, consecutive, nonrandomized, interventional case series.
PARTICIPANTS: Thirty four eyes of 34 patients with CNV secondary to PM. METHODS: Consecutive patients with subfoveal or juxtafoveal CNV secondary to PM were recruited prospectively to receive an intravitreal injection of bevacizumab. Additional injections were performed in eyes with persistent CNV leakage after 2-6 month durations. Patients were followed up for 24 months, and BCVA, changes in FFA and OCT results were assessed.
RESULTS: The mean spherical equivalent refractive error of the 34 eyes was /-3.49 D (range, -6.0D to -19.0D). follow-up period : 24 months. BCVA –improved in 24 eyes(70.6%) –the same in 6 eyes (17.6%) – decreased in 4(11.8%) eyes.
Case received 3 injectionsin 2 years and the CNV is still progressive
2007 Feb 2008 Dec BCVA improved 3 lines from base line
The OCT results also showed significant reduction in thickness after treatment. No systemic complications were noted after intravitreal injections. One eye (2.9%) had an endophthalmitis and resolved on medical treatment. Pre injection 18 month (6 injections
Thirty eyes (88.2%) received multiple injections (2-6 injections) The injection interval varies between 2-13 months
CONCLUSIONS: The 24-month outcomes suggest intravitreal bevacizumab to be a promising treatment method for CNV secondary to PM, resulting in both visual and anatomic improvements.